{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Fulcrum Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"FULC"},"Address":{"label":"Address","value":"26 LANDSDOWNE STREET, CAMBRIDGE, Massachusetts, 02139, United States"},"Phone":{"label":"Phone","value":"+1 617 651-8851"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. It has developed a proprietary product engine that employs to identify and validate cellular drug targets that can modulate gene expression. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle-wasting disorder that leads to physical impairments and disability."},"CompanyUrl":{"label":"Company Url","value":"https://www.fulcrumtx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Alexander C. Sapir","title":"President, Chief Executive Officer & Director"},{"name":"Jeffrey W. Jacobs","title":"Chief Scientific Officer"},{"name":"Mani Sundararajan","title":"Senior Vice President-Technical Operations"},{"name":"Patrick Taylor Horn","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}